Potential Allergen in H1N1 Swine Flu Vaccine May Put Children at Risk
Potential Allergen in H1N1 Swine Flu Vaccine May Put Children at Risk- New Test Reveals Both Presence and Severity of the Allergy
The World Health Organization recently declared H1N1 swine flu a global pandemic, resulting in the creation of rigorous vaccination programs worldwide and anxiety among parents of children with food allergies.
Most H1N1 swine flu vaccines are prepared from virus grown in chicken’s eggs, resulting in a vaccine that contains remnants of egg proteins. Egg allergy is one of the most common food allergies in infants and young children. The allergy can be mild or severe but oftentimes the severity level remains unidentified. Whether a child will be at low or high risk for a clinical reaction as a consequence of receiving this vaccine depends upon the severity of their allergy. As the number of swine flu vaccinations increases, the likelihood of clinical reactions occurring in children with an undetected severe egg allergy intensifies.
Following exposure to egg, children with this allergy may suffer from clinical reactions including rash, gastrointestinal and respiratory infections and even anaphylaxis. In a press release issued last month, the US Food and Drug Administration recommended against H1N1 influenza vaccination for people with severe or life-threatening allergies to chicken eggs. Determining the severity of egg allergy is essential to knowing whether or not a child can safely receive the H1N1 swine flu vaccine.
A new test is available to determine the severity of a child’s egg allergy. A Swedish corporation, Phadia, offers lab testing to accurately diagnose and identify severity level of egg allergy. ImmunoCAP, Phadia’s precise, reliable allergy test that measures IgE antibodies, indicates clinical reaction to both egg white (f1) and ovomucoid (f233). The f1 test will help the physician to confirm or rule out an allergy to egg white. If an allergy to egg white is confirmed, the f233 follow-up test can be conducted to identify the severity of egg allergy and whether the child is at low or high risk for clinical reaction. Phadia is the only company to offer this important follow-up test.
Phadia’s ImmunoCAP allergy test system facilitates diagnosis in children with suspected egg allergy, and, upon diagnosis, determines the level of allergy severity. These tests allow physicians to provide timely advice to parents and caregivers anxious to know whether or not their child should receive the H1N1 swine flu vaccine.
For more information, please contact: Phadia Inc.: Magnus Borres, M.D., Medical Director firstname.lastname@example.org